Scarica l'app Stockscreener
34.80
5.58%
1.84
Dopo l'orario di chiusura:
34.79
-0.010
-0.03%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché VKTX Giù?
Forum
Previsione
Precedente Chiudi:
$32.96
Aprire:
$32.1
Volume 24 ore:
3.59M
Relative Volume:
1.21
Capitalizzazione di mercato:
$4.02B
Reddito:
-
Utile/perdita netta:
$-359.64M
Rapporto P/E:
-10.93
EPS:
-3.1831
Flusso di cassa netto:
$-278.69M
1 W Prestazione:
+1.61%
1M Prestazione:
+4.38%
6M Prestazione:
+24.82%
1 anno Prestazione:
+35.51%
Intervallo 1D:
$32.00
$35.19
Intervallo di 1 settimana:
$29.88
$35.19
Portata 52W:
$18.92
$43.15
Viking Therapeutics Inc Stock (VKTX) Company Profile
Nome
Viking Therapeutics Inc
Settore
Industria
Telefono
858-704-4660
Indirizzo
9920 PACIFIC HEIGHTS BLVD, SUITE 350, SAN DIEGO, CA
Compare VKTX vs VRTX, REGN, ARGX, ALNY, INSM
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
VKTX
Viking Therapeutics Inc
|
34.80 | 4.02B | 0 | -359.64M | -278.69M | -3.1831 |
VRTX
Vertex Pharmaceuticals Inc
|
438.71 | 111.45B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
761.85 | 80.54B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
746.42 | 46.32B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
318.85 | 42.29B | 3.71B | 313.75M | 465.38M | 2.2571 |
INSM
Insmed Inc
|
162.43 | 35.01B | 606.42M | -1.28B | -997.58M | -6.403 |
Viking Therapeutics Inc Stock (VKTX) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-03-26 | Iniziato | Wolfe Research | Peer Perform |
| 2025-10-29 | Iniziato | Canaccord Genuity | Buy |
| 2025-04-29 | Iniziato | Cantor Fitzgerald | Overweight |
| 2025-04-08 | Iniziato | Goldman | Neutral |
| 2025-02-13 | Iniziato | Scotiabank | Sector Outperform |
| 2025-02-07 | Iniziato | Citigroup | Neutral |
| 2024-12-02 | Iniziato | Piper Sandler | Overweight |
| 2024-11-22 | Iniziato | B. Riley Securities | Buy |
| 2024-11-04 | Reiterato | H.C. Wainwright | Buy |
| 2024-09-11 | Iniziato | JP Morgan | Overweight |
| 2024-06-27 | Iniziato | Morgan Stanley | Overweight |
| 2024-05-16 | Aggiornamento | Raymond James | Outperform → Strong Buy |
| 2024-03-26 | Reiterato | Oppenheimer | Outperform |
| 2024-03-07 | Iniziato | Jefferies | Buy |
| 2024-02-28 | Reiterato | Oppenheimer | Outperform |
| 2023-05-31 | Ripresa | ROTH MKM | Buy |
| 2023-03-28 | Reiterato | Maxim Group | Buy |
| 2023-03-17 | Iniziato | Stifel | Buy |
| 2021-07-29 | Ripresa | BTIG Research | Buy |
| 2021-05-25 | Downgrade | Raymond James | Strong Buy → Outperform |
| 2020-06-05 | Iniziato | BMO Capital Markets | Outperform |
| 2020-05-05 | Iniziato | Chardan Capital Markets | Buy |
| 2020-05-01 | Iniziato | BTIG Research | Buy |
| 2019-07-16 | Iniziato | Oppenheimer | Outperform |
| 2019-06-25 | Iniziato | Stifel | Buy |
| 2019-03-29 | Aggiornamento | SVB Leerink | Mkt Perform → Outperform |
| 2019-03-14 | Reiterato | Maxim Group | Buy |
| 2019-02-22 | Iniziato | SVB Leerink | Mkt Perform |
| 2018-12-12 | Iniziato | B. Riley FBR | Buy |
| 2018-11-19 | Aggiornamento | Raymond James | Outperform → Strong Buy |
| 2018-09-18 | Reiterato | H.C. Wainwright | Buy |
| 2018-09-18 | Reiterato | Maxim Group | Buy |
| 2018-09-18 | Reiterato | Raymond James | Outperform |
| 2018-07-20 | Iniziato | SunTrust | Buy |
| 2018-06-28 | Iniziato | Raymond James | Outperform |
| 2018-06-01 | Reiterato | Laidlaw | Buy |
| 2018-05-31 | Reiterato | Maxim Group | Buy |
| 2018-03-26 | Ripresa | H.C. Wainwright | Buy |
| 2017-11-28 | Reiterato | Maxim Group | Buy |
| 2017-11-21 | Iniziato | ROTH Capital | Buy |
Mostra tutto
Viking Therapeutics Inc Borsa (VKTX) Ultime notizie
Viking Therapeutics, Inc. (VKTX) latest stock news and headlines - Yahoo Finance Singapore
Viking Therapeutics, Inc. (VKTX) stock price, news, quote and history - Yahoo Finance Singapore
Viking Therapeutics, Inc. (VKTX) interactive stock chart - Yahoo Finance Singapore
Where Will Viking Therapeutics Stock Be in 10 Years? - The Globe and Mail
Where Will Viking Therapeutics Stock Be in 10 Years? - The Motley Fool
VKTX Stock Rises After-Hours: CNBC Flags Viking As Likely Buyout Target This Year As Big Pharma Hunts Next GLP-1 Winner - Stocktwits
Viking Therapeutics (VKTX) stock has failed to impress since Jim Cramer expressed caution - MSN
VKTX Stock Price, Quote & Chart | VIKING THERAPEUTICS INC (NASDAQ:VKTX) - ChartMill
Viking Therapeutics, Inc. (NASDAQ:VKTX) Given Average Recommendation of "Moderate Buy" by Brokerages - MarketBeat
How (VKTX) Movements Inform Risk Allocation Models - Stock Traders Daily
Here's How Much $100 Invested In Viking Therapeutics 10 Years Ago Would Be Worth Today - Sahm
[ARS] Viking Therapeutics, Inc. SEC Filing - Stock Titan
[DEF 14A] Viking Therapeutics, Inc. Definitive Proxy Statement - Stock Titan
Viking Therapeutics, Inc. (VKTX) declines more than market: Some information for investors - MSN
43,152 Shares in Viking Therapeutics, Inc. $VKTX Purchased by Royal Fund Management LLC - MarketBeat
2 Healthcare Stocks Wall Street Analysts Say Could Rally 60% or More - AOL.com
A Look At Viking Therapeutics (VKTX) Valuation As VANQUISH 2 Enrollment Milestone Advances VK2735 Program - Sahm
Viking Therapeutics, Inc. (VKTX) Declines More Than Market: Some Information for Investors - Yahoo Finance
VKTX stock jumps as retail traders pile into obesity pipeline bets - MSN
The Bull Case For Viking Therapeutics (VKTX) Could Change Following Full VK2735 Phase 3 Enrollment Progress - Sahm
Viking Therapeutics (VKTX) Stock Has Failed To Impress Since Jim Cramer Expressed Caution - Insider Monkey
Viking Therapeutics, Inc. (VKTX) Falls Further Than the Overall Market: What Investors Should Know - Bitget
Viking Therapeutics Approaches Make-or-Break Moment as Key GLP-1 Data Looms - NAI500
Viking Therapeutics moves closer to challenging Ozempic with phase 3 trial progress - MSN
Viking Therapeutics: A Small Biotech Firm Competing in the $100B GLP-1 MarketNews and Statistics - indexbox.io
1 Reason This Biotech Stock Could Triple Before Year-End - Yahoo Finance
VKTX Stock Jumps As Retail Traders Pile Into Obesity Pipeline Bets - stocktwits.com
A Look At Viking Therapeutics (VKTX) Valuation As VK2735 Phase 3 Enrollment Reaches Completion - finance.yahoo.com
Viking Therapeutics Inc (VKTX) Stock Price, Quote, News & History - Benzinga
Viking Therapeutics Trial Milestone Highlights VK2735 And Valuation Gap - simplywall.st
Vanguard disaggregates holdings; reports 0 shares in Viking (VKTX) - Stock Titan
VKTX Completes Participant Recruitment for Second Advanced Clinical Trial of Obesity Medication - Bitget
VKTX Finishes Enrollment in Second Late-Stage Study on Obesity Drug - finance.yahoo.com
Viking Therapeutics completes patient enrolment in VANQUISH-2 trial - Clinical Trials Arena
Viking Therapeutics completes enrollment in obesity drug trial By Investing.com - Investing.com Australia
Published on: 2026-03-27 10:35:11 - baoquankhu1.vn
Better Weight Loss Drug Stock Buy: Eli Lilly vs Viking Therapeutics - AOL.com
VKTX.O - Reuters
Viking Therapeutics (NASDAQ:VKTX) Now Covered by Wolfe Research - MarketBeat
Morgan Stanley reiterates Viking Therapeutics stock rating on trial progress - Investing.com
Viking Therapeutics Moves Closer To Challenging Ozempic With Phase 3 Trial Progress - Stocktwits
Viking Therapeutics (VKTX) Completes Enrollment for Key Clinical Trials - GuruFocus
Viking Therapeutics completes enrollment in obesity drug trial - Investing.com
Viking Therapeutics, Inc. Announces Completion of Enrollment in Phase 3 VANQUISH-2 Trial of VK2735 - MarketScreener
Viking Therapeutics Announces Completion of Enrollment in Phase 3 VANQUISH-2 Trial of VK2735 - nasdaq.com
Is It Too Late To Revisit Viking Therapeutics (VKTX) After Its Multi Year Surge? - simplywall.st
A Stark Divide: Viking Therapeutics' Share Price Lags Far Behind Analyst Conviction - AD HOC NEWS
Meadowbrook Wealth Management LLC Invests $1.31 Million in Viking Therapeutics, Inc. $VKTX - MarketBeat
Why Viking Therapeutics, Inc. (VKTX) dipped more than broader market today - MSN
Viking Therapeutics Secures Manufacturing Might Ahead of Pivotal Data - AD HOC NEWS
Cantor Fitzgerald Initiates Coverage of Viking Therapeutics (VKTX) with Overweight Recommendation - msn.com
Viking Therapeutics Inc Azioni (VKTX) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.49%
1.47%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):